GlassScriptPhysician profile
Essam S Ragheb
NPI 1558340430
$3,146.40
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,333 · 2020: $987 · 2021: $521 · 2022: $180 · 2024: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $124.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $677.51 | 2019-2024 | Airsupra |
| Novo Nordisk INC | $451.22 | 2019-2021 | |
| Glaxosmithkline, LLC. | $319.87 | 2019-2021 | |
| Amgen INC. | $285.83 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.36 | 2019-2022 | |
| Amarin Pharma, INC. | $142.70 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $131.53 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $114.39 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.82 | 2021-2022 | |
| Radius Health, INC. | $93.14 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.83 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $62.28 | 2019-2020 | |
| Daiichi Sankyo INC. | $58.86 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $58.17 | 2019-2020 | |
| Lilly USA, LLC | $56.45 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $52.08 | 2020-2021 | |
| Shire North American Group INC | $35.36 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.33 | 2019 | |
| Allergan, INC. | $19.33 | 2019 | |
| Esperion Therapeutics, INC. | $17.78 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $17.45 | 2022 | |
| Abbott Laboratories | $17.25 | 2021 | |
| Genentech USA, INC. | $16.71 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.99 | 2019 | |
| Abbvie INC. | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Essam Ragheb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.